Get the Stockscreener App
1.216
1.71%
0.0204
After Hours:
1.26
0.044
+3.62%
Tnf Pharmaceuticals Inc stock is traded at $1.216, with a volume of 15,925.
It is up +1.71% in the last 24 hours and down -30.91% over the past month.
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.
See More
Previous Close:
$1.1956
Open:
$1.2
24h Volume:
15,925
Relative Volume:
0.35
Market Cap:
$3.44M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-14.37%
1M Performance:
-30.91%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.19
$1.2685
1-Week Range:
$1.15
$1.42
52-Week Range:
$1.15
$2.16
Tnf Pharmaceuticals Inc Stock (TNFA) Company Profile
Name
Tnf Pharmaceuticals Inc
Sector
Industry
Phone
856-848-8698
Address
855 N. WOLFE STREET, BALTIMORE
Compare TNFA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| TNFA | 1.216 | 3.44M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Tnf Pharmaceuticals Inc Stock (TNFA) Latest News
TNF Pharmaceuticals Inc (TNFA) Quarterly 10-Q Report - Quartzy
TNFA Stock Plummets to 52-Week Low at $1.15 Amid Market Struggles - Investing.com UK
Adalimumab Market 2024: Industry Growth and Future Scope - openPR
Bengals WR Tee Higgins (quad) doubtful for ‘TNF’ vs. Ravens - News- Graphic
TNF Alpha Inhibitors Market Growth Drivers And Trends: Analysis And Forecast 2024-2033 - EIN News
TNF Pharmaceuticals (NASDAQ:TNFA) Stock Quotes, Forecast and News Summary - Benzinga
TNF Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Prevail Partners - Marketscreener.com
TNF Pharmaceuticals : Announces Strategic Equity Investment Priced at a Premium to Market Form 8 K - Marketscreener.com
TNF Pharmaceuticals appoints new auditor amid exit - Investing.com India
TNF Pharmaceuticals appoints new auditor amid exit By Investing.com - Investing.com South Africa
Stock Market Movers Today • Top Gainers & Losers - Benzinga
TNF Pharmaceuticals Secures Strategic Equity Investment from Prevail Partners - citybiz
TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market - BioSpace
TNF Pharmaceuticals announces investment from Prevail Partners - TipRanks
Tumor Necrosis Factor Inhibitor Drugs Market to hit USD 50 billion by 2032, says Global Market Insights Inc. - GlobeNewswire
In Crohn's Disease, Higher Early Anti-TNF Levels May Be Crucial to Treatment Success - Medscape
United States Tumor Necrosis Factor Receptor Superfamily Member 9 Market By Application - Third Eye News
Sarcopenia Market Anticipates Impressive Growth Trajectory - GlobeNewswire
TNF Pharmaceuticals sets date for 2024 annual meeting - Investing.com India
TNF Pharmaceuticals sets date for 2024 annual meeting By Investing.com - Investing.com Canada
Tumor Necrosis Factor Inhibitor Drugs Market Insights Discussed Regarding Trends and Forecast Report 2024-2033 - WhaTech
North Face Parent V.F. Corp To Improve Gradually In Next Four To Six Quarters, Analyst Upgrades Stock - Yahoo Finance
PharmaCyte Biotech, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2024 - Marketscreener.com
Tnf LLC Decreases Stock Holdings in Amazon.com, Inc. (NASDAQ:AMZN) - Defense World
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab - StockTitan
North America Autoimmune Monoclonal Antibodies Market By Application - Third Eye News
Bills QB Josh Allen (hand) cleared for TNF vs. Dolphins - News- Graphic
TNF Week 1: Ravens-Chiefs Preview, Props, Prediction - News- Graphic
TNFA stock touches 52-week low at $1.62 amid market challenges - Investing.com UK
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.com
Tnf LLC Has $2.38 Million Position in Exxon Mobil Co. (NYSE:XOM) - Defense World
North America Chronic Intestinal Inflammation Treatment Drug Market Size, Share, Forecast, [2030] - அக்னி செய்திகள்
TNF Pharmaceuticals to initiate MYMD-1 Phase II clinical trials - Yahoo Finance
TNF Pharmaceuticals advances MYMD-1 trials for inflammation - Investing.com
TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline - StockTitan
Eleven option delistings on August 19th - TipRanks
TNF Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
TNF Pharmaceuticals, Inc. announced that it expects to receive $14 million in funding from PharmaCyte Biotech, Inc. - Marketscreener.com
Tumor Necrosis Factor Inhibitor Drugs Market: An Extensive Analysis Predicts Significant Future Growth - openPR
Tumor Necrosis Factor Inhibitor Drugs Market Size Report, 2032 - Global Market Insights
Adalimumab Biosimilar Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
Forward Therapeutics discovers TNF-α production inhibitors - BioWorld Online
TNF Pharmaceuticals expands share count in strategic move - Investing.com India
MyMD Pharmaceuticals Rebrands as TNF Pharmaceuticals - TipRanks
TNF Pharmaceuticals debuts new ticker symbol TNFA - Investing.com
TNF Pharmaceuticals debuts new ticker symbol TNFA By Investing.com - Investing.com Nigeria
TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today - Business Wire
Tnf Pharmaceuticals Inc Stock (TNFA) Financials Data
There is no financial data for Tnf Pharmaceuticals Inc (TNFA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):